Home › Funds › Samsara BioCapital, LLC › XFOR
Samsara BioCapital, LLC position in XFOR
X4 PHARMACEUTICALS INC · Health Care
Samsara BioCapital, LLC reported holding 1,347,723 shares of XFOR (X4 PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$3.9M, representing 0.37% of its reported portfolio and ranking #24 among its reported holdings. Samsara BioCapital, LLC has disclosed XFOR holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Samsara BioCapital, LLC's XFOR position evolved
Samsara BioCapital, LLC first disclosed a stake in XFOR in Q4 2025 at 1,960,000 shares (US$7.8M). Across 4 filings, Samsara BioCapital, LLC increased the stake 0 time(s), trimmed it 3 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 1,347,723 shares valued at US$3.9M — a reduction of -47,864 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 1.96M | $7.84M | New |
| Q1 2026 | 1.83M | $7.57M | Reduce |
| Q2 2026 | 1.40M | $6.52M | Reduce |
| Q3 2026 | 1.35M | $3.91M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About XFOR and 13F data
XFOR (X4 PHARMACEUTICALS INC) is a Health Care company. 36 other funds we track also report a position in XFOR — the largest reported positions include Empery Asset Management, LP (US$28.2M), Bain Capital Life Sciences Investors, LLC (US$23.1M), Venrock Adviser, LLC (US$22.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding XFOR
- Empery Asset Management, LP 9.73M sh · $28.20M · Q3 2026
- Bain Capital Life Sciences Investors, LLC 7.97M sh · $23.11M · Q3 2026
- Venrock Adviser, LLC 7.64M sh · $22.17M · Q3 2026
- Saturn V Capital Management LP 7.37M sh · $21.36M · Q3 2026
- PERCEPTIVE ADVISORS LLC 7.35M sh · $21.32M · Q3 2026
- Kalehua Capital Management LLC 3.72M sh · $10.80M · Q3 2026
- NEA Management Company, LLC 3.23M sh · $9.38M · Q3 2026
- Rosalind Advisors, Inc. 3.21M sh · $9.32M · Q3 2026
- Trails Edge Capital Partners, LP 2.57M sh · $7.46M · Q3 2026
- BVF INC/IL 1.58M sh · $4.57M · Q3 2026
- Verdad Advisers, LP 323.17K sh · $937.18K · Q3 2026
More on Samsara BioCapital, LLC
FAQ
How long has Samsara BioCapital, LLC held XFOR?
Samsara BioCapital, LLC has disclosed XFOR holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is Samsara BioCapital, LLC's current position in XFOR?
As of Q3 2026, Samsara BioCapital, LLC holds 1.35M shares of XFOR (X4 PHARMACEUTICALS INC), valued at $3.91M, representing 0.37% of its reported portfolio and ranking #24.
Has Samsara BioCapital, LLC been buying or selling XFOR?
In the latest 13F filing (Q3 2026), Samsara BioCapital, LLC reduced its position in XFOR.
Which other funds hold XFOR?
Other major institutional holders of XFOR include Empery Asset Management, LP, Bain Capital Life Sciences Investors, LLC, Venrock Adviser, LLC, among 36 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.